Abstract
Background Sleepio is an automated digital programme that delivers cognitive behavioural therapy for insomnia. Sleepio has been proven effective in improving sleep difficulties. However, evidence for the possible impact of Sleepio use on health care costs in the United Kingdom has not previously been developed. In this study, we assessed the effect of a population-wide rollout of Sleepio in terms of primary care costs in the National Health Service (NHS) in England.
Methods The study was conducted in the Thames Valley region of England, where access to Sleepio was made freely available to all residents between October 2018 and January 2020. We use primary care data for people with relevant characteristics from nine general practices in Buckinghamshire. The study relies on a quasi-experimental design, using an interrupted time series to compare the trend in primary care costs before and after the rollout of Sleepio. Primary care costs include general practice contacts and prescriptions. Segmented regression analysis was used to estimate primary and secondary outcomes.
Results For the 10,704 patients included in our sample, the total saving over the 65-week follow-up period was £71,027. This corresponds to £6.64 per person in our sample or around £70.44 per Sleepio user. Secondary analyses suggest that savings may be driven primarily by reductions in prescriptions.
Conclusion Sleepio rollout reduced primary care costs. National adoption of Sleepio may reduce primary care costs by £20 million in the first year. The expected impact on primary care costs in any particular setting will depend on the uptake of Sleepio.
Competing Interest Statement
CS, EB, and AC are employed by the Office of Health Economics, which has received funding from Big Health (the developers of Sleepio).
Funding Statement
This study was funded by Oxford AHSN and by Big Health Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involved no randomisation, did not require changes to accepted treatment standards within the NHS, and did not involve primary data collection. The study was retrospectively reviewed by the Joint Research Office study classification group at Oxford University Hospitals NHS Foundation Trust and classified as service evaluation, such that it did not require research ethics board approval. The study received permission from Buckinghamshire Clinical Commissioning Group's Medicines Management Assurance Committee. All Sleepio participants agreed to a privacy policy when they registered for Sleepio and consented to Big Health Ltd. using health information for research purposes. This allows for non-identifiable health information only to be published in aggregate form for academic research. Collection and analysis of data within the Sleepio programme was approved by the Medical Sciences Interdivisional Research Ethics Committee, University of Oxford (Ref R72295/RE001).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study used no identifiable information. As per the study's data sharing agreements, the data cannot be made available to other researchers.
